Beam Therapeutics Q2 2026: Net Loss Widens, CEO Adopts 10b5-1 Plan, BEAM-302 Pivotal Cohort Dosed
BEAM sits 63% above its 52-week low of $15.6.
Summary
Beam Therapeutics posted a $122.7M Q2 net loss with $1.2B in cash. Clinical catalysts include BEAM-302 pivotal dosing and BEAM-304 IND clearance, but the CEO's adoption of a 10b5-1 trading plan introduces a potential overhang.
Key Events · Earnings and Guidance · BEAM
-
Q2 2026 Financial Results
Net loss of $122.7 million on revenue of $0.5 million. Cash, equivalents, and marketable securities totaled $1.2 billion as of June 30, 2026, expected to fund operations for at least 12 months.
-
CEO Adopts 10b5-1 Trading Plan
CEO John Evans adopted a Rule 10b5-1 plan on June 16, 2026, for the potential sale of up to 200,000 shares through June 30, 2027.
-
BEAM-302 Pivotal Cohort Initiated
The first patient was dosed in the pivotal expansion cohort of the BEAM-302 Phase 1/2 trial in July 2026, supporting a potential accelerated approval pathway in AATD.
-
BEAM-304 IND Cleared
The FDA cleared the IND for BEAM-304 in June 2026, and clinical startup activities have begun for a Phase 1/2 trial in phenylketonuria.
Analysis · BEAM · Life Sciences
A net loss of $122.7 million on minimal revenue underscores the pre-commercial stage, yet a $1.2 billion cash position provides ample runway. Clinically, the quarter delivered two milestones: dosing began in the BEAM-302 pivotal cohort, and the FDA cleared the IND for BEAM-304, allowing Phase 1/2 startup activities to commence. Tempering the outlook, CEO John Evans adopted a Rule 10b5-1 trading plan covering up to 200,000 shares. Meanwhile, the Apellis collaboration concluded, and Biogen closed its acquisition of Apellis. The balance sheet carries $100.3 million in debt from a new credit facility. Updated risk factors flag ongoing CRISPR patent interference proceedings that could challenge Beam's intellectual property.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BEAM was trading at $25.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $15.60 to $38.26. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.